You are here:

MS in the media - 26 May 2017

Published on

20 - 26 May 2017

These are links to news stories from the last week that may be of interest to people in the UK. The link beneath each item will take you to the original story.

Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.

To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for Open Door, our free newsletter or regular email alerts

Biotin trial planned

An international trial of biotin in people with progressive MS is due to start later this year. UK centres shown on the clinical webpage will be in Edinburgh, London and Salford.

Source: MS News Today

MS Trust link: Biotin (MD1003)

Ozanimod trail results

A phase III trial comparing ozanimod and Avonex as a treatment for people with relapsing MS, found that the drug was more successful at reducing the relapse rate - though no figures are given. Ozanimod didn't show any significant difference in slowing build-up of disability

Source: Celgene press release
Source: National MS Society (USA)

MS Trust link: Encouraging results from earlier ozanimod drug trial

Gilenya effect on relapses

A study of people taking Gilenya (fingolimod) found the drug reduced relapses by 75% over the first two years. People for whom it was their first disease modifying drug saw a bigger reduction (85%) than those who had had a previous treatment (67%).

Source: MS News Today

MS Trust link: Gilenya (fingolimod)

Neurological Alliance manifesto

The Neurological Alliance has put together a list of five issues that it wants General Election candidates to address: access to specialist care; support from primary care professionals; research into new and better treatments; shared decision making and equitable access to treatments; mental health needs of people with neurological conditions

Source: Neurological Alliance

MS Trust link: A new manifesto for neurology services in England

Fampridine granted full licence

Based on the results of the ENHANCE trial into the long-term benefits of fampridine (Fampyra), the European Commission has granted a standard marketing authorization. The research addressed the issues that led to fampridine previously only having a conditional licence. The change of licence is unlikely to have an effect on the decision by NICE that fampridine is not a cost effective treatment

Source: Biogen press release

MS Trust link: Fampridine (Fampyra)

Case of PML in Ocrevus

Someone in Germany who was taking Ocrevus (ocrelizumab) has been diagnosed with the brain infection, PML. They had previously been taking Tysabri (natalizumab) for three years. The cause of PML in this case is unclear and being investigated

Source: MedPage Today
Source: National MS Society (USA)

MS Trust link: Progressive multifocal leukoencephalopathy (PML)

Print this page